In HER2+/estrogen receptor (ER)-positive breast cancer, maintenance treatment with trastuzumab, pertuzumab, and hormonal therapy is usually given after a fixed number of cycles of trastuzumab, pertuzumab, and docetaxel induction [21]. The gene discussed is ESR1; the disease is breast carcinoma.